Related Experiment Video
Updated: Jun 18, 2026
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
Published on: February 3, 2026
A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer
Yousuke Nakai1, Hiroyuki Isayama, Takashi Sasaki
1Department of Gastroenterology, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
Objectives:
We performed a pilot study of a modified combination chemotherapy regimen with S-1 plus gemcitabine for patients with advanced pancreatic cancer.
Methods:
Gemcitabine was administered at a dose of 1,000 mg/m(2) in a 30-min intravenous injection on days 1 and 15. S-1 was administered orally at a dose of 40 mg/m(2) twice daily for 14 consecutive days followed by a 14-day rest. Each cycle was repeated every 28 days.
Results:
Sixteen patients were enrolled. No complete response was observed and partial response was observed in 5 patients (31.3%), stable disease in 10 patients (62.5%) and progressive disease in 1 patient (6.3%). The median time to progression was 10.0 months (95% CI 4.4-N.A.) and the median survival time was 20.4 months (95% CI 8.6-24.1 months). The major toxicities were grade 3 neutropenia (25.0%) and grade 3 anemia (6.3%). There were no grade 4 toxicities.
Conclusions:
Combination therapy with gemcitabine and S-1 using the modified 4-week schedule was well tolerated and efficacious for advanced pancreatic cancer.
